B细胞-话题@MedSci

#B细胞#

314篇内容 | 4759人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1273360, encodeId=d5fa12e3360ac, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=FDA批准治疗复发或难治性大B细胞淋巴瘤患者的口服药物：核出口抑制剂XPOVIO, objectType=article, longId=196393, objectId=d7b919639342, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7b919639342, replyNumber=0, likeNumber=54, createdTime=2020-06-25, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7b919639342, moduleTitle=FDA批准治疗复发或难治性大B细胞淋巴瘤患者的口服药物：核出口抑制剂XPOVIO, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d7b919639342)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273359, encodeId=0e2212e335947, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Truxima、来那度胺和acalabrutinib方案治疗复发难治性侵袭性B细胞淋巴瘤：安全有效, objectType=article, longId=196009, objectId=77a7196009ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77a7196009ec, replyNumber=0, likeNumber=55, createdTime=2020-06-18, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77a7196009ec, moduleTitle=Truxima、来那度胺和acalabrutinib方案治疗复发难治性侵袭性B细胞淋巴瘤：安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77a7196009ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273358, encodeId=ca9812e33583b, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Lancet oncol：Tafasitamab联合来那度胺治疗复发/难治性弥漫性大B细胞淋巴瘤的疗效, objectType=article, longId=195473, objectId=16a61954e3e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16a61954e3e1, replyNumber=0, likeNumber=83, createdTime=2020-06-09, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16a61954e3e1, moduleTitle=Lancet oncol：Tafasitamab联合来那度胺治疗复发/难治性弥漫性大B细胞淋巴瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16a61954e3e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273357, encodeId=05fa12e33573f, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=CAR-T治疗复发B细胞急性淋巴细胞白血病患儿获得完全缓解, objectType=article, longId=195407, objectId=8e5719540e54, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e5719540e54, replyNumber=0, likeNumber=78, createdTime=2020-06-07, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e5719540e54, moduleTitle=CAR-T治疗复发B细胞急性淋巴细胞白血病患儿获得完全缓解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e5719540e54)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273356, encodeId=819a12e33560b, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=NEJM：高风险、成熟的B细胞非霍奇金淋巴瘤儿童利妥昔单抗疗效分析 , objectType=article, longId=195309, objectId=a2e71953094c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2e71953094c, replyNumber=0, likeNumber=104, createdTime=2020-06-06, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2e71953094c, moduleTitle=NEJM：高风险、成熟的B细胞非霍奇金淋巴瘤儿童利妥昔单抗疗效分析 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2e71953094c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273355, encodeId=026e12e3355cb, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=JCO：CAR-T用于复发或难治性大B细胞淋巴瘤真实世界数据发布，结果与试验结果一致, objectType=article, longId=194692, objectId=93bf194692fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93bf194692fc, replyNumber=0, likeNumber=100, createdTime=2020-05-26, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93bf194692fc, moduleTitle=JCO：CAR-T用于复发或难治性大B细胞淋巴瘤真实世界数据发布，结果与试验结果一致, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93bf194692fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273354, encodeId=b4f512e33544b, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Blood：E3连接酶UBR5突变调控淋巴瘤B细胞成熟, objectType=article, longId=193441, objectId=7b7a1934410d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b7a1934410d, replyNumber=0, likeNumber=137, createdTime=2020-05-05, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b7a1934410d, moduleTitle=Blood：E3连接酶UBR5突变调控淋巴瘤B细胞成熟, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b7a1934410d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273353, encodeId=108112e335383, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Brit J Heamatol：他汀类药物和环氧合酶2抑制剂可提高弥漫性大B细胞淋巴瘤患者的存活率, objectType=article, longId=193101, objectId=1e4d193101ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e4d193101ba, replyNumber=0, likeNumber=85, createdTime=2020-04-30, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e4d193101ba, moduleTitle=Brit J Heamatol：他汀类药物和环氧合酶2抑制剂可提高弥漫性大B细胞淋巴瘤患者的存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e4d193101ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273352, encodeId=97cd12e3352f5, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Allergy：过敏性鼻炎中CD23的表达建立T-B细胞互作 , objectType=article, longId=192430, objectId=d3c6192430ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3c6192430ea, replyNumber=0, likeNumber=55, createdTime=2020-04-19, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3c6192430ea, moduleTitle=Allergy：过敏性鼻炎中CD23的表达建立T-B细胞互作 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3c6192430ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273351, encodeId=b34212e335144, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=BJH：儿童复发/难治性侵袭性B细胞非霍奇金淋巴瘤的治疗新进展, objectType=article, longId=191606, objectId=a4ff1916061e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4ff1916061e, replyNumber=0, likeNumber=83, createdTime=2020-04-08, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4ff1916061e, moduleTitle=BJH：儿童复发/难治性侵袭性B细胞非霍奇金淋巴瘤的治疗新进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a4ff1916061e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273350, encodeId=d77212e335069, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=中国MNPA批准细胞疗法GC007g治疗CD19阳性复发难治B细胞急性淋巴细胞白血病的IND, objectType=article, longId=191470, objectId=27641914e046, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27641914e046, replyNumber=0, likeNumber=73, createdTime=2020-04-06, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27641914e046, moduleTitle=中国MNPA批准细胞疗法GC007g治疗CD19阳性复发难治B细胞急性淋巴细胞白血病的IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27641914e046)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273349, encodeId=764412e3349d8, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Cell Death Dis：肿瘤微环境浸润B细胞通过IL-1β/HIF-2α/ Notch1信号促进肾癌转移, objectType=article, longId=190441, objectId=8ef8190441e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ef8190441e0, replyNumber=0, likeNumber=80, createdTime=2020-03-21, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ef8190441e0, moduleTitle=Cell Death Dis：肿瘤微环境浸润B细胞通过IL-1β/HIF-2α/ Notch1信号促进肾癌转移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ef8190441e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273348, encodeId=fe0c12e334877, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Cell Death & Disease：肿瘤驯化的B细胞能够促进肾癌的转移 , objectType=article, longId=190410, objectId=1c0919041072, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c0919041072, replyNumber=0, likeNumber=96, createdTime=2020-03-21, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c0919041072, moduleTitle=Cell Death & Disease：肿瘤驯化的B细胞能够促进肾癌的转移 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c0919041072)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273347, encodeId=7e1a12e334754, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Hepatology：B细胞介导的分化簇的维持169-阳性细胞对于肝再生至关重要, objectType=article, longId=190315, objectId=76131903158c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76131903158c, replyNumber=0, likeNumber=53, createdTime=2020-03-20, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76131903158c, moduleTitle=Hepatology：B细胞介导的分化簇的维持169-阳性细胞对于肝再生至关重要, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76131903158c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273346, encodeId=339b12e33466d, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Blood：CVID的非接纳骨髓微环境影响B细胞的早期发育, objectType=article, longId=189802, objectId=897e18980253, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=897e18980253, replyNumber=0, likeNumber=89, createdTime=2020-03-13, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=897e18980253, moduleTitle=Blood：CVID的非接纳骨髓微环境影响B细胞的早期发育, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=897e18980253)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273345, encodeId=c0a612e334569, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=NCCN临床实践指南：B细胞淋巴瘤（2020.V1）, objectType=article, longId=188974, objectId=ae461889e4c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae461889e4c5, replyNumber=0, likeNumber=52, createdTime=2020-03-01, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae461889e4c5, moduleTitle=NCCN临床实践指南：B细胞淋巴瘤（2020.V1）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae461889e4c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273344, encodeId=49d312e3344ac, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=J Hepatology：慢性乙肝患者的乙型肝炎核心特异性记忆B细胞的临床反应变化, objectType=article, longId=188594, objectId=2de618859436, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2de618859436, replyNumber=0, likeNumber=123, createdTime=2020-02-24, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2de618859436, moduleTitle=J Hepatology：慢性乙肝患者的乙型肝炎核心特异性记忆B细胞的临床反应变化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2de618859436)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273343, encodeId=8e0412e33432e, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=FDA接受Karyopharm的口服核出口选择性抑制剂XPOVIO的补充新药申请，用于治疗复发或难治的弥漫性大B细胞淋巴瘤, objectType=article, longId=188486, objectId=9acb18848624, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9acb18848624, replyNumber=0, likeNumber=72, createdTime=2020-02-22, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9acb18848624, moduleTitle=FDA接受Karyopharm的口服核出口选择性抑制剂XPOVIO的补充新药申请，用于治疗复发或难治的弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9acb18848624)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273342, encodeId=977312e334223, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=FDA批准Liso-cel治疗B细胞淋巴瘤的优先审查, objectType=article, longId=188100, objectId=0b4e188100f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b4e188100f8, replyNumber=0, likeNumber=81, createdTime=2020-02-16, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b4e188100f8, moduleTitle=FDA批准Liso-cel治疗B细胞淋巴瘤的优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b4e188100f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273341, encodeId=d08012e334121, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Cell Death Dis：新型HDAC抑制剂西达本胺可与利妥昔单抗协同抑制弥漫性大B细胞淋巴瘤, objectType=article, longId=187714, objectId=782818e714bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=782818e714bf, replyNumber=0, likeNumber=70, createdTime=2020-02-10, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=782818e714bf, moduleTitle=Cell Death Dis：新型HDAC抑制剂西达本胺可与利妥昔单抗协同抑制弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=782818e714bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

B细胞

2020-05-29

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

FDA批准治疗复发或难治性大B细胞淋巴瘤患者的口服药物：核出口抑制剂XPOVIO

2020-06-25

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Truxima、来那度胺和acalabrutinib方案治疗复发难治性侵袭性B细胞淋巴瘤：安全有效

2020-06-18

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Lancet oncol：Tafasitamab联合来那度胺治疗复发/难治性弥漫性大B细胞淋巴瘤的疗效

2020-06-09

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

CAR-T治疗复发B细胞急性淋巴细胞白血病患儿获得完全缓解

2020-06-07

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

NEJM：高风险、成熟的B细胞非霍奇金淋巴瘤儿童利妥昔单抗疗效分析

2020-06-06

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

JCO：CAR-T用于复发或难治性大B细胞淋巴瘤真实世界数据发布，结果与试验结果一致

2020-05-26

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Blood：E3连接酶UBR5突变调控淋巴瘤B细胞成熟

2020-05-05

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Brit J Heamatol：他汀类药物和环氧合酶2抑制剂可提高弥漫性大B细胞淋巴瘤患者的存活率

2020-04-30

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Allergy：过敏性鼻炎中CD23的表达建立T-B细胞互作

2020-04-19

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

BJH：儿童复发/难治性侵袭性B细胞非霍奇金淋巴瘤的治疗新进展

2020-04-08

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

中国MNPA批准细胞疗法GC007g治疗CD19阳性复发难治B细胞急性淋巴细胞白血病的IND

2020-04-06

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Cell Death Dis：肿瘤微环境浸润B细胞通过IL-1β/HIF-2α/ Notch1信号促进肾癌转移

2020-03-21

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Cell Death & Disease：肿瘤驯化的B细胞能够促进肾癌的转移

2020-03-21

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Hepatology：B细胞介导的分化簇的维持169-阳性细胞对于肝再生至关重要

2020-03-20

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Blood：CVID的非接纳骨髓微环境影响B细胞的早期发育

2020-03-13

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

NCCN临床实践指南：B细胞淋巴瘤（2020.V1）

2020-03-01

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

J Hepatology：慢性乙肝患者的乙型肝炎核心特异性记忆B细胞的临床反应变化

2020-02-24

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

FDA接受Karyopharm的口服核出口选择性抑制剂XPOVIO的补充新药申请，用于治疗复发或难治的弥漫性大B细胞淋巴瘤

2020-02-22

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

FDA批准Liso-cel治疗B细胞淋巴瘤的优先审查

2020-02-16

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Cell Death Dis：新型HDAC抑制剂西达本胺可与利妥昔单抗协同抑制弥漫性大B细胞淋巴瘤

2020-02-10

科室
- - 订阅+
  - 更多科室
工具
服务